Home Technology Orexigen Therapeutics Continues to Rally

Orexigen Therapeutics Continues to Rally

When you purchase through our sponsored links, we may earn a commission. By using this website you agree to our T&Cs.

Caesars Entertainment Corp (NASDAQ:CZR), Orexigen Therapeutics, Inc. (NASDAQ:OREX) and Fossil Group Inc (NASDAQ:FOSL) reached midday with major gains. Taking tumbles midday are Altisource Portfolio Solutions S.A. (NASDAQ:ASPS), Cal Dive International, Inc. (OTCMKTS:CDVI) and Stemline Therapeutics Inc (NASDAQ:STML).

Caesars Surges Thanks to Credit Agreement

Caesars Entertainment Corp (NASDAQ:CZR) reached midday up +27.11% thanks to reports that it has reached an agreement with creditors regarding its debt restructuring plan. Leon Cooperman, John Paulson and George Soros have positions in the casino operator, which despite today’s gain is down -34.03% YTD.

The share price of Orexigen Therapeutics, Inc. (NASDAQ:OREX) climbed +18.95% early in the day today, putting its five-day gain at +48.15%. The drug developer has gained 74.36% over the past month – much to the benefit of Farallon Capital, which as of Q2 holds 2.68 million OREX shares.


Fossil Group Inc (NASDAQ:FOSL) got an +8.16% boost this morning after surpassing analysts’ estimates on earnings and announcing a renewed deal with Michael Kors (NYSE:KORS). The company, a Ray Dalio holding, has gained +9.66% over the last three months.

Altisource Portfolio Solutions Plunges

Altisource Portfolio Solutions S.A. (NASDAQ:ASPS) plunged -21.8% today, hitting a new low after announcing that it is discontinuing its Lender Placed Insurance brokerage line of business. ASPS, a long-time Leon Cooperman holding, has declined -63.4% year-to-date.

Cal Dive International, Inc. (OTCMKTS:CDVI) continues its freefall, its price dipping -21.74% by midday today. The company was delisted from the New York Stock Exchange just last week – a tough break for billionaire investor George Soros.

Also having a rough go this Wednesday is Stemline Therapeutics Inc (NASDAQ:STML), the share price of which fell -7.56% despite beating expectations on earnings. STML, a Farallon Capital holding, is down -28.47% YTD.

Sign Up For Our Free Newsletter


Our Editorial Standards

At ValueWalk, we’re committed to providing accurate, research-backed information. Our editors go above and beyond to ensure our content is trustworthy and transparent.


Want Financial Guidance Sent Straight to You?

  • Pop your email in the box, and you'll receive bi-weekly emails from ValueWalk.
  • We never send spam — only the latest financial news and guides to help you take charge of your financial future.